Table 1.
Variable | All (n=35 ECMO runs) | Age ≤30 days (n=21 ECMO runs) | Age >30 days (n=14 ECMO runs) | p |
---|---|---|---|---|
| ||||
Age, median (IQR) | 10d (2d – 10y) | 3d (1d – 9d) | 11y (5m – 15y) | <0.001 |
| ||||
Male, n(%) | 16 (44) | 9 (43) | 10 (71) | 0.096 |
| ||||
Race | ||||
Caucasian, n(%) | 16 (46) | 9 (43) | 7 (50) | 0.538 |
African American, n(%) | 14 (40) | 9 (43) | 5 (36) | |
Other, n(%) | 5 (14) | 3 (14) | 2 (14) | |
| ||||
ECMO indications, n(%) | ||||
Respiratory failure | 18 (51) | 17 (81) | 1 (7) | <0.001 |
Cardiac failure | 9 (26) | 3 (14) | 6 (43) | |
ECPR | 7 (20) | 1 (5) | 6 (43) | |
Sepsis | 1 (3) | 0 | 1 (7) | |
| ||||
ECMO mode | ||||
VA-ECMO | 29 (83) | 16 (76) | 13 (93) | 0.311 |
VV-ECMO | 3 (9) | 3 (14) | 0 | |
VV- to VA-ECMO | 3 (9) | 2 (10) | 1 (7) | |
| ||||
ECMO duration, median(IQR) | 7d (3d – 14d) | 12d (6d – 15d) | 3.5d (1d – 5d) | 0.006 |
| ||||
Neurologic injury during ECMO, n(%)* | 12 (34) | 7 (33) | 5 (36) | 0.884 |
| ||||
Survival to discharge, n(%) | 24 (69) | 18 (86) | 6 (43) | 0.007 |
| ||||
Circuit clotting requiring circuit replacement, n(%) | 14 (40) | 12 (57) | 2 (14) | 0.011 |
| ||||
Oxygenator failure, n(%) | 6 (17) | 5 (24) | 1 (7) | 0.200 |
| ||||
ε-aminocaproic acid use, n(%)† | 9 (26) | 5 (24) | 4 (29) | 0.752 |
| ||||
Hemorrhagic complications, n(%) | ||||
ICH | 7 (20) | 5 (24) | 2 (14) | 0.490 |
Pulmonary hemorrhage | 7 (20) | 5 (24) | 2 (14) | 0.490 |
Other (hemothorax, adrenal hemorrhage, retroperitoneal hemorrhage) | 4 (11) | 2 (10) | 2 (14) | 0.664 |
Neurologic injury during ECMO is defined as: intracranial hemorrhage, ischemic stroke, cerebral edema or brain death.
No antifibrinolytic agents other than ε-aminocaproic acid were used in this cohort of patients.